Hennion & Walsh Asset Management Inc. Buys 1,445 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Hennion & Walsh Asset Management Inc. grew its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 2.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,289 shares of the company’s stock after acquiring an additional 1,445 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.07% of Day One Biopharmaceuticals worth $979,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in Day One Biopharmaceuticals by 38.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock worth $5,486,000 after purchasing an additional 125,050 shares during the last quarter. Trexquant Investment LP bought a new position in Day One Biopharmaceuticals in the 3rd quarter valued at $1,201,000. Schonfeld Strategic Advisors LLC increased its stake in Day One Biopharmaceuticals by 18.3% in the third quarter. Schonfeld Strategic Advisors LLC now owns 136,700 shares of the company’s stock worth $1,677,000 after purchasing an additional 21,182 shares during the period. Alps Advisors Inc. increased its stake in Day One Biopharmaceuticals by 2.5% in the third quarter. Alps Advisors Inc. now owns 64,153 shares of the company’s stock worth $787,000 after purchasing an additional 1,592 shares during the period. Finally, TimesSquare Capital Management LLC boosted its stake in shares of Day One Biopharmaceuticals by 41.8% during the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock valued at $14,020,000 after purchasing an additional 336,910 shares during the period. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Price Performance

DAWN opened at $13.58 on Tuesday. The firm has a market capitalization of $1.19 billion, a PE ratio of -5.41 and a beta of -1.51. The business’s 50-day moving average is $14.52 and its two-hundred day moving average is $14.77. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Monday, May 6th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). As a group, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -2.69 EPS for the current year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, Director Saira Ramasastry sold 10,000 shares of the stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $13.19, for a total value of $131,900.00. Following the completion of the sale, the director now directly owns 40,485 shares in the company, valued at $533,997.15. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Saira Ramasastry sold 10,000 shares of the stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $13.19, for a total value of $131,900.00. Following the transaction, the director now directly owns 40,485 shares of the company’s stock, valued at $533,997.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeremy Bender sold 9,154 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $17.85, for a total value of $163,398.90. Following the completion of the transaction, the chief executive officer now owns 642,602 shares of the company’s stock, valued at $11,470,445.70. The disclosure for this sale can be found here. Insiders have sold a total of 185,534 shares of company stock worth $3,207,830 in the last ninety days. 8.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. JPMorgan Chase & Co. raised their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday, April 22nd. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, June 20th. Needham & Company LLC restated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, June 19th. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.